Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Orchestra BioMed Holdings (OBIO) EBIT (2022 - 2025)

Historic EBIT for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Q3 2025 value amounting to -$20.3 million.

  • Orchestra BioMed Holdings' EBIT fell 2429.94% to -$20.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$75.2 million, marking a year-over-year decrease of 2517.76%. This contributed to the annual value of -$64.3 million for FY2024, which is 2484.18% down from last year.
  • According to the latest figures from Q3 2025, Orchestra BioMed Holdings' EBIT is -$20.3 million, which was down 2429.94% from -$19.3 million recorded in Q2 2025.
  • In the past 5 years, Orchestra BioMed Holdings' EBIT registered a high of -$5.1 million during Q1 2022, and its lowest value of -$20.3 million during Q3 2025.
  • Moreover, its 4-year median value for EBIT was -$14.4 million (2024), whereas its average is -$13.8 million.
  • In the last 5 years, Orchestra BioMed Holdings' EBIT crashed by 12513.65% in 2023 and then crashed by 1251.72% in 2024.
  • Quarter analysis of 4 years shows Orchestra BioMed Holdings' EBIT stood at -$9.8 million in 2022, then fell by 26.99% to -$12.5 million in 2023, then plummeted by 33.62% to -$16.7 million in 2024, then decreased by 21.8% to -$20.3 million in 2025.
  • Its EBIT was -$20.3 million in Q3 2025, compared to -$19.3 million in Q2 2025 and -$18.9 million in Q1 2025.